The trajectory of Sildenafil presents a complex case for observers in the medicinal sector. While initially a phenomenal success, generating vast sums, the patent lapse and the subsequent entry of generic competitors have drastically impacted earnings. This poses questions about the ongoing viability of related medication innovations and suggest… Read More